2,4,5-Trifluorophenylacetic Acid CAS 209995-38-0 Purity ≥99.5% (GC) Sitagliptin Phosphate Monohydrate Intermediate

Chemical Name: 2,4,5-Trifluorophenylacetic Acid  CAS: 209995-38-0 Purity: ≥99.5% (GC) Appearance: White to Off-White Powder Intermediate of Sitagliptin Phosphate Monohydrate (CAS: 654671-77-9) for the treatment of type 2 diabetes High Quality, Commercial Production E-Mail: alvin@ruifuchem.com

Products Details

Chemical Properties:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.Supply Sitagliptin Phosphate Monohydrate Related Intermediates: Sitagliptin API CAS 486460-32-6 Sitagliptin Phosphate Monohydrate API CAS 654671-77-9 2,4,5-Trifluorophenylacetic Acid CAS 209995-38-0 Boc-(R)-3-Amino-4-(2,4,5-Trifluoro-Phenyl)-Butyric Acid CAS 486460-00-8 Sitagliptin Triazole Hydrochloride CAS 762240-92-6 Sitagliptin Phosphate Monohydrate Intermediate CAS 486460-21-3
Item Specifications
Appearance White to Off-White Powder
Purity / Analysis Method ≥99.5% (GC) 
Moisture (K.F) ≤0.50%
Residue on Igniton ≤0.50%
Total Impurities ≤0.50%
Test Standard Enterprise Standard
Usage Intermediate of Sitagliptin Phosphate Monohydrate (CAS: 654671-77-9)

Description:

Specifications:

Package & Storage:

Chemical Name 2,4,5-Trifluorophenylacetic Acid
CAS Number 209995-38-0
CAT Number RF-PI1191
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C8H5F3O2
Molecular Weight 190.12
Melting Point 121.0 to 125.0℃
Solubility Soluble in Methanol
Brand Ruifu Chemical

Advantages:

FAQ:

Application:

2,4,5-Trifluorophenylacetic Acid (CAS: 209995-38-0) is an intermediate of Sitagliptin Phosphate Monohydrate (CAS: 654671-77-9). Sitagliptin Phosphate (STG) is used to treat DM type 2 because it improves glycemic control by increasing the levels of active incretin hormones, GLP-1 (peptide-1) and GIP (glucose-dependent insulinotropic peptide). The activation of these incretins in β-pancreatic cells causes increased levels of cyclic adenosine monophosphate (cAMP) and intracellular calcium, with subsequent glucose-dependent insulin secretion (2). This hypoglycemic drug belongs to a new class called dipeptidyl peptidase IV inhibitors. STG was approved by the FDA in 2006.

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours